Cartesian Therapeutics and Beyond Air: A Stock Comparison Guide

In a detailed comparison of two small-cap medical companies, Cartesian Therapeutics (NASDAQ: RNAC) and Beyond Air (NASDAQ: XAIR), analysts are evaluating their investment potential based on various financial metrics. The analysis focuses on institutional ownership, profitability, earnings, and market recommendations to determine which stock may be a more favorable investment choice.

Analyst Recommendations and Target Prices

Analysts currently favor Beyond Air over Cartesian Therapeutics, as indicated by target price projections. Cartesian Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 468.86%. In contrast, Beyond Air boasts a higher consensus target price of $11.00, which implies a remarkable potential upside of 1,362.38%. Given these figures, analysts convey a stronger belief in the potential of Beyond Air as a more attractive investment.

Profitability and Risk Assessment

When evaluating volatility, Cartesian Therapeutics has a beta of 0.36, indicating its share price is 64% less volatile than the S&P 500. Beyond Air has an even lower beta of 0.3, suggesting its share price is 70% less volatile than the index. This lower volatility may appeal to risk-averse investors looking for stability in their portfolios.

In terms of ownership, institutional investors hold 86.9% of shares in Cartesian Therapeutics, compared to just 31.5% for Beyond Air. Additionally, company insiders own 60.3% of Cartesian Therapeutics shares, while 19.4% of shares in Beyond Air are held by insiders. High institutional ownership often indicates confidence in a company’s long-term performance from major investors.

Both companies have shown differing earnings and valuation metrics. Beyond Air currently reports higher revenue and earnings compared to Cartesian Therapeutics. However, Cartesian Therapeutics trades at a lower price-to-earnings ratio, suggesting it may be a more affordable option for investors looking for value.

Company Profiles

Cartesian Therapeutics, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases. The firm is developing Descartes-08, an innovative therapy currently in Phase 2b clinical trials targeting conditions such as generalized myasthenia gravis and systemic lupus erythematosus. Other products include Descartes-15 and Descartes-33, with the latter still in preclinical development.

Beyond Air, located in Garden City, New York, operates as a commercial-stage medical device and biopharmaceutical company. The company is known for its LungFit platform, which includes a nitric oxide generator and delivery system. LungFit PH is designed for treating persistent pulmonary hypertension in newborns, while LungFit PRO targets viral lung infections, including COVID-19. The company previously operated under the name AIT Therapeutics, Inc. before rebranding in June 2019.

In summary, while Cartesian Therapeutics demonstrates strong institutional backing and lower volatility, Beyond Air offers a higher potential upside and greater revenue. Investors should consider these factors along with their individual risk tolerance when evaluating these two companies.